Beginning with SARS, Ebola, Zika, MERS, and now COVID-19, the world has witnessed the magnitude of the threat from the outbreak of an infectious and deadly disease. The subsequent scramble for a vaccine, and the long delays involved, makes it clear that we are unprepared. Why are we underinvesting in the R&D necessary for the rapid deployment of crucial medicines?